JP1520 PIK3CA H1047R HA Citations (4)

Originally described in: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS Cancer Res. 2005 Dec 1. 65(23):10992-1000. PubMed Journal

---

Articles Citing JP1520 PIK3CA H1047R HA

Articles
Repression of cancer cell senescence by PKCiota. Paget JA, Restall IJ, Daneshmand M, Mersereau JA, Simard MA, Parolin DA, Lavictoire SJ, Amin MS, Islam S, Lorimer IA. Oncogene. 2012 Aug 2;31(31):3584-96. doi: 10.1038/onc.2011.524. Epub 2011 Nov 28. PubMed
Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A. Cancer Res. 2016 Dec 9. pii: canres.2400.2016. PubMed
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Wang Q, Shi YL, Zhou K, Wang LL, Yan ZX, Liu YL, Xu LL, Zhao SW, Chu HL, Shi TT, Ma QH, Bi J. Cell Death Dis. 2018 Jul 3;9(7):739. doi: 10.1038/s41419-018-0776-6. PubMed
Hypoxia destroys the microstructure of microtubules and causes dysfunction of endothelial cells via the PI3K/Stathmin1 pathway. Cao H, Yu D, Yan X, Wang B, Yu Z, Song Y, Sheng L. Cell Biosci. 2019 Feb 18;9:20. doi: 10.1186/s13578-019-0283-1. eCollection 2019. PubMed

If you have published an article using this material, please email us at to have your article added to this page.